Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices 12487 

TABLE 2—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR section 589.2001(f) Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

respondent 

Total hours 

One-time (initial) burden ...................................................... 1 1 1 80 80 

Burden from future review ................................................... 1 1 1 26 26 

1There are no capital costs or operating costs associated with the collection of information. 

Description of Respondents for 

Reporting: The final regulation on BSE 

(73 FR 22720) included a provision that 

exempts cattle materials prohibited in 

animal feed (CMPAF) from designated 

countries from the prohibition on its use 

in animal feed. A foreign country 

seeking this designation will submit a 

written request to FDA that includes a 

variety of information about the 

country’s BSE status (§ 589.2001(f)). 

During the past 6 years, FDA received 

2 requests from countries to be 

exempted from CMPAF restrictions. 

One-Time (Initial) Reporting Burden 

There is a one-time burden to 

countries that apply to FDA seeking to 

be designated as not subject to 

restrictions applicable to CMPAF. We 

estimate that each country that applies 

for an exclusion will spend 80 hours 

putting information together to submit 

to FDA. Table 2 row 1 presents the onetime burden for the exclusion. (See final 

BSE regulation at 73 FR 22754). 

Recurring Burden 

Countries that successfully petition 

FDA to be designated as exempt from 

certain BSE-related restrictions 

applicable to animal feed will be subject 

to future review by FDA to ensure that 

their designation remains appropriate. 

As part of this process, FDA may ask 

designated countries from time-to-time 

to confirm that their BSE situation and 

the information submitted by them in 

support of their original application 

remains unchanged. We assume it will 

take FDA and the designated country 

undergoing a review in the future about 

one third the time and effort it did when 

the information was submitted. Table 2 

row 2 presents the expected recurring 

burden. 

Dated: March 2, 2015. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2015–05356 Filed 3–6–15; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel Small Business Innovation 

Research (SBIR). 

Date: March 31, 2015. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Rahat Khan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, 6701 Democracy 

Blvd., Rm 1078, Bethesda, MD 20892, 301– 

894–7319, khanr2@csr.nih.gov. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel CTSA Meeting 1. 

Date: April 8–9, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Carol Lambert, Ph.D., 

Acting Deputy Director, Office of Grants 

Management & Scientific Review, National 

Center for Advancing Translational Sciences 

(NCATS) National Institutes of Health, 6701 

Democracy Boulevard, Democracy 1, Room 

1076, Bethesda, MD 20892, 301–435–0814, 

lambert@mail.nih.gov. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel 2015 CTSA Application 

Review. 

Date: April 15–16, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Washington/Rockville 1750 

Rockville Pike, Rockville, MD 20852. 

Contact Person: Guo He Zhang, Ph.D., 

MPH, Scientific Review Office, Office of 

Grants Management & Scientific Review, 

National Center for Advancing Translational 

Sciences (NCATS) National Institutes of 

Health, 6701 Democracy Boulevard, 

Democracy 1, Room 1064, Bethesda, MD 

20892, 301–435–0812, zhanggu@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B–Cooperative Agreements; 

93.859, Biomedical Research and Research 

Training, National Institutes of Health, HHS). 

Dated: March 3, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–05304 Filed 3–6–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request Surveys and 

Interviews To Support an Evaluation of 

the Innovative Molecular Analysis 

Technologies (IMAT) Program (NCI) 

SUMMARY: Under the provisions of 

section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH), has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. This proposed information 

collection was previously published in 

the Federal Register on December 4, 

2014, Vol. 79, Page 72004 and allowed 

60-days for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. The 

National Cancer Institute (NCI), 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

mstockstill on DSK4VPTVN1PROD with NOTICES

12488 Federal Register / Vol. 80, No. 45 / Monday, March 9, 2015 / Notices 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid OMB control number. 

Direct Comments to OMB: Written 

comments and/or suggestions regarding 

the item(s) contained in this notice, 

especially regarding the estimated 

public burden and associated response 

time, should be directed to the: Office 

of Management and Budget, Office of 

Regulatory Affairs, OIRA_submission@

omb.eop.gov or by fax to 202–395–6974, 

Attention: NIH Desk Officer. 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments or request more 

information on the proposed project 

contact: Anthony Dickherber, NCI 

Center for Strategic Scientific Initiatives, 

31 Center Drive, Rm10A33, Bethesda, 

MD 20892 or call non-toll-free number 

301–547–9980 or Email your request, 

including your address to: 

dickherberaj@mail.nih.gov. Formal 

requests for additional plans and 

instruments must be requested in 

writing. 

Proposed Collection: Surveys and 

Interviews to Support an Evaluation of 

the Innovative Molecular Analysis 

Technologies (IMAT) Program (NCI), 

0925–NEW, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The purpose of the proposed 

evaluation is to pursue a comprehensive 

process and outcome assessment of the 

15-year old Innovative Molecular 

Analysis Technologies (IMAT) program. 

While the program consistently offers 

promising indicators of success, the full 

program has not been evaluated since 

2008, and never in as comprehensive a 

manner as has been formulated in the 

current evaluation plan. An outcome 

evaluation of the long-standing National 

Cancer Institute’s (NCI) IMAT program 

presents a rich and unique opportunity 

likely to serve institutes across the 

National Institutes of Health (NIH), and 

perhaps other federal agencies, 

considering the costs and benefits of 

directing resources towards supporting 

technology development. An award 

through the NIH Evaluation Set-Aside 

program to support this evaluation, for 

which NIH-wide relevance is a principle 

element of determining merit for 

support, is testament to this. The 

evaluation serves as an opportunity to 

gauge the impact of investments in 

technology development and also to 

assess the strengths and weaknesses of 

phased innovation award mechanisms. 

Like all institutes and centers (ICs) of 

the NIH, NCI seeks opportunities for 

improving their programs’ utility for the 

broad continuum of researchers, 

clinicians and ultimately patients. NCI 

Director Harold Varmus and other 

leadership across NCI, as well as the 

NCI Board of Scientific Advisors, will 

be the primary users of the evaluation 

results. Findings are primarily intended 

for considering the long-term strategy to 

support innovative technology 

development and how to more 

efficiently translate emerging 

capabilities through such technologies 

into the promised benefits for cancer 

research and clinical care. Interviews 

with grantees, program officers, review 

officers, and other NIH awardees make 

up a crucial component of the 

evaluation plan and will largely follow 

set survey protocols. Specific near-term 

aims include the use of this information 

to consider the utility of continued 

investment through existing 

solicitations and in strategic planning 

generally for institute support for 

innovative technology development. 

OMB approval is requested for 1 year. 

There are no costs to respondents other 

than their time. The total estimated 

annualized burden hours are 575. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of 

respondents 

Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden 

(in hours) 

IMAT Awardee Interview ............... IMAT Awardees ............................................... 100 1 1 100 

Evaluation Web-based Survey ...... IMAT Applicants and Other NIH Awardees ..... 900 1 30/60 450 

Tech End Users Interview ............. Technology End-Users .................................... 50 1 30/60 25 

Dated: February 23, 2015. 

Karla Bailey, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. 2015–05298 Filed 3–6–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10555] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

any of the following subjects: (1) The 

necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions; 

(2) the accuracy of the estimated 

burden; (3) ways to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) the use of 

automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments must be received by 

May 8, 2015. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

mstockstill on DSK4VPTVN1PROD with NOTICES